CEBPA and acute myeloid leukemia: We also examined mutation risk groups/molecular subgroups and found that Hispanic patients were more likely to have an adverse risk AML fusion [11q23, inv(3), t(6;9)], and non‐Hispanic patients were more likely to have a favorable risk fusion/mutation [t(8;21), inv(16), NPM1, CEBPA].